Ashfield Capital Partners LLC Has $3.38 Million Position in SPDR S&P Biotech ETF (XBI)

Ashfield Capital Partners LLC boosted its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 38.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,228 shares of the exchange traded fund’s stock after purchasing an additional 9,705 shares during the period. Ashfield Capital Partners LLC’s holdings in SPDR S&P Biotech ETF were worth $3,377,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in XBI. Morgan Stanley grew its position in SPDR S&P Biotech ETF by 23.8% in the second quarter. Morgan Stanley now owns 9,568,839 shares of the exchange traded fund’s stock valued at $910,858,000 after purchasing an additional 1,840,100 shares in the last quarter. Assetmark Inc. grew its position in shares of SPDR S&P Biotech ETF by 271,147.4% in the 2nd quarter. Assetmark Inc. now owns 1,264,013 shares of the exchange traded fund’s stock valued at $120,321,000 after acquiring an additional 1,263,547 shares during the period. SG Americas Securities LLC grew its position in shares of SPDR S&P Biotech ETF by 159.3% in the 2nd quarter. SG Americas Securities LLC now owns 977,702 shares of the exchange traded fund’s stock valued at $93,067,000 after acquiring an additional 600,603 shares during the period. Harel Insurance Investments & Financial Services Ltd. grew its position in shares of SPDR S&P Biotech ETF by 9,533.7% in the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 209,437 shares of the exchange traded fund’s stock valued at $20,079,000 after acquiring an additional 207,263 shares during the period. Finally, Howard Capital Management grew its position in shares of SPDR S&P Biotech ETF by 557.2% in the 2nd quarter. Howard Capital Management now owns 151,047 shares of the exchange traded fund’s stock valued at $14,378,000 after acquiring an additional 128,065 shares during the period.

Shares of XBI opened at $83.96 on Monday. SPDR S&P Biotech ETF has a one year low of $76.37 and a one year high of $101.55.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Article: What Are Treasury Bonds?

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply